Sign in

CIK 0001570562

  • Accelerated filer

Evolus, Inc.

Sign in to watch
Ticker
EOLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
461385614
Phone
+1 949-284-4555
Business address
520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH, CA, 92660
Former names
Evolus, Inc.
  1. 4 Planned sale Chief Financial Officer sold 1,821 shares at $13.08 ($23,821)
  2. 4 Grant or award Director acquired 6,464 shares (grant or award)
  3. 4 Grant or award Director acquired 6,464 shares (grant or award)
  4. 4 Grant or award Director acquired 6,464 shares (grant or award)
  5. 4 Grant or award Director acquired 6,464 shares (grant or award)
  6. 4 Grant or award Director acquired 6,464 shares (grant or award)
  7. 4 Grant or award Director acquired 6,464 shares (grant or award)
  8. 4 Grant or award Chief Marketing Officer acquired 24,648 shares (grant or award)
  9. 4 Grant or award Chief Financial Officer acquired 35,211 shares (grant or award)
  10. 4 Grant or award See Remarks acquired 35,211 shares (grant or award)
  11. 4 Grant or award See Remarks acquired 134,976 shares (grant or award)
  12. 4 Planned sale Director sold 11,931 shares at $13.14 ($156,733)
  13. 4 Open-market sale See Remarks sold 82,648 shares at an average $9.95 ($822,396)
  14. 4 Open-market sale Former 10% Owner sold 1,690,663 shares at $7.50 ($12,679,973)
  15. 4 Planned sale Chief Financial Officer sold 3,178 shares at $9.70 ($30,827)
  16. 4 Grant or award Chief Marketing Officer acquired 63,358 shares (grant or award)
  17. 3 Insider Initial Statement of Ownership
  18. 4 Planned sale See Remarks sold 2,211 shares at $10.27 ($22,707)
  19. 4 Planned sale Chief Financial Officer sold 2,211 shares at $10.27 ($22,707)
  20. 4 Planned sale See Remarks sold 14,778 shares at $10.27 ($151,770)

Page 4 of 13 · 252 filings